In the complex and often controversial world of pharmaceutical pricing, a $37,000-a-year medicine is emerging as an unexpected model for […]
How a $37,000-a-year medicine sets a good model for drug pricing Read Post »
Three Big Mistakes Drug Companies Make in Recruiting New Employees In the fast-paced world of biopharmaceuticals, recruiting top talent is
3 big mistakes drug companies make in recruiting new employees Read Post »
The biopharmaceutical industry stands at a crossroads. The era of blockbuster drugs, once the lifeblood of big pharma, is waning.
As blockbuster drugs fizzle, biotech looks warily to the next big thing Read Post »
File this under ‘unintended consequences.’ A number of health care organizations are complaining that a final guideline the US Food
Americans overspend $73bn on branded drugs Read Post »
By Dylan Scott, Posted with permission from STAT Mark Cuban has something to say about prescription drug prices. The billionaire
Mark Cuban Sounds Off on Drug Prices Read Post »
Some Biosimilars Are Just as Good as Some Pricey Biologics: A Game-Changer in Healthcare In the world of medicine, we’re
Some biosimilars are just as good as some pricey biologics Read Post »
Thank you for your interest in submitting a guest article! Submit your guest article here DrugPatentWatch is interested in sharing
DrugPatentWatch Guest Article Agreement Read Post »
Hermann A. M. Mucke*, H. M. Pharma Consultancy, Wien, Austria A Multimodal Approach to the Re-development of Drugs Drug repositioning—the
Drug Repositioning in the Mirror of Patenting: Surveying and Mining Uncharted Territory Read Post »
Share your expertise with our expansive network > Go to submission form < Do you want to reach a large
Publish With DrugPatentWatch Read Post »
Get fresh news and insights, drug patent expirations & more…
